SubscribeLatest 5 articles from heartwire
- Air pollutants mediate effects on heart health through inflammation and thrombosis
May 17, 2012 17:15 EDT - Statins benefit those at much lower CV risk
May 16, 2012 18:30 EDT - Azithromycin may up chance of sudden cardiac death
May 16, 2012 17:00 EDT - So long, Plavix, what a ride! Clopidogrel patent expires
May 16, 2012 14:45 EDT - COMFORTABLE-AMI: Bioerodable polymer DES trumps bare metal in STEMI
May 16, 2012 10:50 EDT
MAGELLAN on VTE, EXCELLENT on antiplatelets, and OSCAR on antihypertensives
Posted Apr 05, 2011
at 06:50 PM, EDT
by Avi Sherman
On the closing day of the American College of Cardiology (ACC) 2011 Scientific Sessions prevention of venous thromboembolism, duration of dual antiplatelet therapies, and antihypertensive treatment for the elderly made the news. Watch analysis of the top trials.
See:
MAGELLAN: Rivaroxaban prevents VTE in medical patients, but bleeding an issue
EXCELLENT results for stopping DAPT at six months, but others say bigger trials are needed
OSCAR: Antihypertensive choice in elderly should be guided by underlying disease
Previous posts
"Consent the stent" campaign--long overdue!
No comments |
Posted May 09, 2012
at 10:05 PM, EDT by Melissa
at 10:05 PM, EDT by Melissa
Hospital interest rates: Taking the family farm
10 Comments |
Posted Apr 24, 2012
at 08:22 PM, EDT by Melissa
at 08:22 PM, EDT by Melissa
Dr Dean Ornish with manna for the masses
16 Comments |
Posted Mar 28, 2012
at 10:05 AM, EDT by Melissa
at 10:05 AM, EDT by Melissa
Physicians remember: Mainstream-medicine haters are people too
24 Comments |
Posted Mar 27, 2012
at 12:37 PM, EDT by Melissa
at 12:37 PM, EDT by Melissa
All natural? $15 billion worth sold annually
19 Comments |
Posted Mar 27, 2012
at 12:36 AM, EDT by Melissa
at 12:36 AM, EDT by Melissa
Also from theheart.org
Comments